{
 "cells": [
  {
   "cell_type": "markdown",
   "id": "f68c300d-94a4-4bc6-be02-65b072a0cc22",
   "metadata": {},
   "source": [
    "# AI-Guided Patient Selection for Lu-177 PSMA Therapy\n",
    "\n",
    "**Competition:** Kaggle Google AI Hackathon - Health AI Developer Foundations  \n",
    "**Author:** Amy Cheruto Siele  \n",
    "**Institution:** University of Nairobi | RFH Healthcare Kenya  \n",
    "**Date:** February 2026\n",
    "\n",
    "---\n",
    "\n",
    "## Overview\n",
    "\n",
    "This demo showcases an AI-powered clinical decision support system for Lu-177 PSMA radioligand therapy patient selection.\n",
    "\n",
    "**The Problem:**\n",
    "- 40-60% of patients selected by SUV criteria alone don't respond (Peters et al., 2022)\n",
    "- 12% experience severe nephrotoxicity (Sartor et al., 2021)\n",
    "- Clinicians lack tools to interpret dosimetry data in clinical context\n",
    "\n",
    "**The Solution:**\n",
    "- Open-source dosimetry pipeline ‚Üí quantitative kidney doses\n",
    "- Gemini AI (HAI-DEF) ‚Üí evidence-based clinical recommendations\n",
    "- Structured guidance for therapy eligibility, dose adjustments, monitoring\n",
    "\n",
    "**Innovation:**\n",
    "First application of HAI-DEF to theranostic patient selection, bridging quantitative dosimetry and clinical decision-making.\n",
    "\n",
    "---"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 1,
   "id": "13c94a54-cfc7-49f0-9387-44c8ad0e9c39",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ Imports successful!\n",
      "‚úÖ Gemini AI Clinical Assistant ready to load\n"
     ]
    }
   ],
   "source": [
    "# Setup and Imports\n",
    "import os\n",
    "import sys\n",
    "\n",
    "# Add src directory to path\n",
    "sys.path.append('../' if os.path.exists('../gemini_helper.py') else './')\n",
    "\n",
    "from gemini_helper import ClinicalAssistant\n",
    "\n",
    "print(\"‚úÖ Imports successful!\")\n",
    "print(\"‚úÖ Gemini AI Clinical Assistant ready to load\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 2,
   "id": "ac8f4b82-9016-42c4-9e56-9ee102628bb4",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "‚úÖ Google API key found!\n"
     ]
    }
   ],
   "source": [
    "# Set API key (make sure it's set in your environment)\n",
    "api_key = os.environ.get('GOOGLE_API_KEY')\n",
    "\n",
    "if api_key:\n",
    "    print(\"‚úÖ Google API key found!\")\n",
    "else:\n",
    "    print(\"‚ùå API key not found!\")\n",
    "    print(\"Run in terminal: set GOOGLE_API_KEY=your_key_here\")"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 3,
   "id": "e60405b7-418c-42da-ad58-40e809b282c2",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Initializing Gemini AI Clinical Assistant...\n",
      "‚úÖ Gemini Clinical Assistant ready!\n",
      "\n",
      "======================================================================\n",
      "READY FOR CLINICAL DECISION SUPPORT\n",
      "======================================================================\n"
     ]
    }
   ],
   "source": [
    "# Initialize Gemini Clinical Assistant\n",
    "print(\"Initializing Gemini AI Clinical Assistant...\")\n",
    "assistant = ClinicalAssistant()\n",
    "print(\"\\n\" + \"=\"*70)\n",
    "print(\"READY FOR CLINICAL DECISION SUPPORT\")\n",
    "print(\"=\"*70)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "11dbdc68-6cf1-44de-93dc-67c0794b36d2",
   "metadata": {},
   "source": [
    "---\n",
    "\n",
    "## Demo Case 1: Clear Eligibility ‚úÖ\n",
    "\n",
    "**Patient Profile:**\n",
    "- Kidney dose (Ga-68): 10 Gy\n",
    "- eGFR: 70 mL/min\n",
    "- No prior kidney disease\n",
    "- Good performance status\n",
    "\n",
    "**Expected:** Standard protocol recommended"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "a0cd065a-eb01-4029-8e44-230f26d286ed",
   "metadata": {},
   "source": [
    "# Case 1: Clear Eligibility\n",
    "print(\"Running AI eligibility assessment...\\n\")\n",
    "\n",
    "recommendation = assistant.check_eligibility(\n",
    "    kidney_dose=10.0,\n",
    "    egfr=70,\n",
    "    predicted_lu_dose=14.7,\n",
    "    kidney_history=\"None\"\n",
    ")\n",
    "\n",
    "print(recommendation)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "8c502c6a-400a-46d3-8cfe-bd5fb53fbe2b",
   "metadata": {},
   "source": [
    "---\n",
    "\n",
    "## Demo Case 2: Borderline Eligibility (AI Nuanced Guidance) ‚ö†Ô∏è\n",
    "\n",
    "**Patient Profile:**\n",
    "- Kidney dose (Ga-68): 12.5 Gy\n",
    "- eGFR: 45 mL/min (Stage 3a CKD)\n",
    "- Prior kidney disease: Chronic kidney disease\n",
    "- Predicted Lu-177 dose: 18.3 Gy\n",
    "\n",
    "**Expected:** Eligible WITH modifications"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 5,
   "id": "79e5b6e9-2ba7-4b79-bd2b-b7bc6af58c59",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Running AI eligibility assessment for borderline case...\n",
      "\n",
      "Based on the provided patient data and current EANM practical guidance for Lu-177 PSMA radioligand therapy (version 2023), here is the assessment:\n",
      "\n",
      "---\n",
      "\n",
      "1.  **Eligibility:** **Yes, but with significant modifications and careful monitoring.**\n",
      "\n",
      "2.  **Key Considerations:**\n",
      "    *   **Cumulative Kidney Absorbed Dose Limit:** The EANM guidelines recommend a cumulative kidney absorbed dose limit of **40 Gy**. The predicted Lu-177 kidney dose of 18.3 Gy for what is presumed to be a *single cycle* of treatment is high. This means that if standard activities are administered, only 2 cycles (36.6 Gy) would be feasible before approaching the 40 Gy limit, and a third cycle at this predicted dose would exceed it. This necessitates careful planning for the total number of cycles or dose reduction per cycle.\n",
      "    *   **Baseline Renal Function:** The eGFR of 45 mL/min/1.73m¬≤ (Stage 3a CKD) indicates moderately decreased kidney function. While there is no absolute eGFR cutoff for Lu-177 PSMA therapy, patients with eGFR < 60 mL/min/1.73m¬≤ are at increased risk for renal toxicity and require heightened vigilance and potential dose adjustments. This is the most critical factor for this patient.\n",
      "    *   **Diagnostic Ga-68 Kidney Dose:** The Ga-68 scan kidney absorbed dose of 12.5 Gy is a high diagnostic dose and serves as a precursor to the predicted therapeutic Lu-177 dose. It highlights that this patient likely has significant kidney uptake of PSMA-targeting agents, which is reflected in the high predicted Lu-177 dose. It does not directly add to the cumulative Lu-177 therapeutic dose limit but underscores the need for careful dosimetry.\n",
      "    *   **Prior Kidney Disease:** Stage 3a CKD confirms the compromised baseline renal function, increasing the susceptibility to further renal damage from radiation.\n",
      "    *   **Risk-Benefit Assessment:** The potential benefits of Lu-177 PSMA therapy must be carefully weighed against the heightened risk of irreversible renal function decline in this patient.\n",
      "\n",
      "3.  **Dose Recommendations:**\n",
      "    *   **Individualized Dosimetry-Guided Dosing:** Given the high predicted kidney dose and compromised renal function, patient-specific dosimetry is paramount. Instead of administering a fixed activity, the dose should be tailored to achieve a target kidney absorbed dose per cycle (e.g., 6-8 Gy per cycle, or even lower, depending on the therapeutic objective and overall treatment plan), ensuring the cumulative 40 Gy limit is not exceeded.\n",
      "    *   **Consider Reduced Activity:** A reduction in the administered Lu-177 activity per cycle may be necessary to lower the dose per cycle to the kidneys, allowing for more cycles if clinically indicated, or to minimize the risk of acute renal injury.\n",
      "    *   **Aggressive Hydration:** Standard and intensified hydration protocols, including pre- and post-therapy intravenous fluids, are crucial to promote renal clearance and minimize kidney residence time.\n",
      "    *   **Amino Acid Co-infusion:** Mandatory renal protection using amino acid solutions (e.g., Lysine and Arginine) should be strictly adhered to, initiating before Lu-177 administration and continuing for the recommended duration.\n",
      "\n",
      "4.  **Monitoring Requirements:**\n",
      "    *   **Pre-Therapy:** Comprehensive baseline assessment of renal function (eGFR, creatinine, BUN, urinalysis) and blood counts.\n",
      "    *   **During Therapy (Between Cycles):**\n",
      "        *   **Renal Function:** Close monitoring of eGFR, serum creatinine, and BUN before each subsequent cycle. A significant decline (e.g., >25% from baseline or progression to stage 4 CKD) would necessitate re-evaluation of treatment continuation or further dose reduction.\n",
      "        *   **Blood Counts:** Routine monitoring of complete blood count (CBC) to assess for hematological toxicity.\n",
      "    *   **Post-Therapy Dosimetry:** **Essential** to perform post-treatment dosimetry after *each* Lu-177 cycle to accurately calculate the cumulative kidney absorbed dose. This information is critical for planning subsequent cycles and ensuring the 40 Gy cumulative limit is not breached.\n",
      "    *   **Long-Term Follow-up:** Regular monitoring of renal function and blood counts for an extended period after the completion of therapy.\n",
      "    *   **Clinical Surveillance:** Close monitoring for any clinical signs or symptoms of renal insufficiency (e.g., edema, changes in urine output, fatigue).\n",
      "\n",
      "---\n"
     ]
    }
   ],
   "source": [
    "# Case 2: Borderline - Stage 3a CKD\n",
    "print(\"Running AI eligibility assessment for borderline case...\\n\")\n",
    "\n",
    "recommendation = assistant.check_eligibility(\n",
    "    kidney_dose=12.5,\n",
    "    egfr=45,\n",
    "    predicted_lu_dose=18.3,\n",
    "    kidney_history=\"Stage 3a CKD\"\n",
    ")\n",
    "\n",
    "print(recommendation)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "b1ce8849-44e6-499b-8e95-e23bd7a3b55f",
   "metadata": {},
   "source": [
    "---\n",
    "\n",
    "## Demo Case 3: High Risk (Cautious Recommendation) üö´\n",
    "\n",
    "**Patient Profile:**\n",
    "- Kidney dose (Ga-68): 20 Gy\n",
    "- eGFR: 35 mL/min (Stage 3b CKD)\n",
    "- Prior kidney disease: Moderate chronic kidney disease\n",
    "- Predicted Lu-177 dose: 29.4 Gy\n",
    "\n",
    "**Expected:** High nephrotoxicity risk, consider alternatives"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": 6,
   "id": "fe97e8de-7fd5-44d3-8078-4ba009f8bb77",
   "metadata": {},
   "outputs": [
    {
     "name": "stdout",
     "output_type": "stream",
     "text": [
      "Running AI eligibility assessment for high-risk case...\n",
      "\n",
      "Here is the assessment of the patient's eligibility for Lu-177 PSMA therapy based on EANM guidelines:\n",
      "\n",
      "---\n",
      "\n",
      "1.  **Eligibility:** With modifications\n",
      "\n",
      "    The patient's eGFR of 35 mL/min/1.73m¬≤ (corresponding to Stage 3b CKD) indicates impaired renal function. According to EANM guidelines (e.g., Fendler et al., 2017), the recommended cumulative kidney absorbed dose limit for patients with impaired renal function (eGFR < 60 mL/min/1.73m¬≤) is approximately **23 Gy**.\n",
      "\n",
      "    The predicted Lu-177 kidney dose for this patient is 29.4 Gy, which significantly exceeds this recommended cumulative limit of 23 Gy for patients with pre-existing renal impairment. Therefore, the patient is **not eligible** for therapy that would result in a cumulative kidney dose of 29.4 Gy.\n",
      "\n",
      "    However, the patient may be considered eligible if the administered activity per cycle and/or the total number of cycles are significantly reduced to ensure the total cumulative kidney absorbed dose remains below or equal to 23 Gy. The initial kidney absorbed dose of 20.0 Gy (from the Ga-68 scan) likely reflects pre-therapeutic dosimetry, contributing to the prediction of 29.4 Gy for Lu-177. If the 20 Gy was a prior received Lu-177 dose, then the total cumulative dose would be 49.4 Gy, making the patient definitively ineligible. Assuming 29.4 Gy is the total predicted dose for the planned therapy, the dose must be reduced.\n",
      "\n",
      "2.  **Key considerations:**\n",
      "\n",
      "    *   **Pre-existing Renal Impairment:** The patient has Stage 3b CKD, which significantly increases the risk of further and irreversible deterioration of renal function with radioligand therapy.\n",
      "    *   **Kidney Dosimetry:** The predicted cumulative kidney dose of 29.4 Gy is substantially higher than the EANM recommended limit of 23 Gy for patients with impaired renal function. This is the primary limiting factor for standard treatment.\n",
      "    *   **Benefit-Risk Assessment:** A careful, multidisciplinary discussion is crucial to weigh the potential oncologic benefits of Lu-177 PSMA therapy against the high risk of accelerating renal failure, given the patient's baseline kidney function and high predicted dose.\n",
      "    *   **Renal Protective Measures:** Aggressive renal protective strategies, particularly robust amino acid co-infusion, are paramount to minimize kidney uptake and potential toxicity.\n",
      "\n",
      "3.  **Dose recommendations:**\n",
      "\n",
      "    *   **Strict Dose Reduction:** The total cumulative administered activity of Lu-177 PSMA must be substantially reduced to ensure the total cumulative kidney absorbed dose does not exceed **23 Gy**. This will require a significant reduction from the currently predicted dose target of 29.4 Gy.\n",
      "    *   **Personalized Dosimetry:** Meticulous patient-specific dosimetry, preferably involving pre-therapeutic Lu-177 trace dose imaging (theragnostic approach), is essential to accurately predict and confirm the actual kidney dose for each cycle.\n",
      "    *   **Fractionation Strategy:** Carefully consider the activity per cycle and the total number of cycles to remain strictly within the 23 Gy cumulative limit. A single kidney absorbed dose should generally not exceed 7.5-8 Gy.\n",
      "    *   **Amino Acid Co-infusion:** Continue with a standard and optimized amino acid co-infusion protocol for renal protection.\n",
      "    *   **Hydration:** Ensure excellent pre-, during, and post-therapy hydration.\n",
      "\n",
      "4.  **Monitoring requirements:**\n",
      "\n",
      "    *   **Renal Function:** Close and frequent monitoring of eGFR, serum creatinine, and blood urea nitrogen (BUN) is mandatory. This should be performed before each treatment cycle, at regular intervals during treatment (e.g., monthly), and for an extended period post-therapy (e.g., every 3 months for the first year, then annually).\n",
      "    *   **Urinalysis:** Regular assessment for proteinuria, microhematuria, and other markers of renal damage.\n",
      "    *   **Blood Pressure:** Monitor and aggressively manage blood pressure, as hypertension can exacerbate renal dysfunction.\n",
      "    *   **Hematology:** Monitor complete blood count (CBC) to assess for bone marrow toxicity, which can be an independent side effect.\n",
      "    *   **Clinical Symptoms:** Monitor for any signs or symptoms related to renal impairment (e.g., edema, fatigue, electrolyte imbalances) or other treatment-related toxicities.\n",
      "    *   **Long-term Nephrological Follow-up:** Given the pre-existing CKD and the need for significant dose modifications, long-term follow-up by a nephrologist is highly recommended to manage renal health.\n"
     ]
    }
   ],
   "source": [
    "# Case 3: High Risk - Severe CKD\n",
    "print(\"Running AI eligibility assessment for high-risk case...\\n\")\n",
    "\n",
    "recommendation = assistant.check_eligibility(\n",
    "    kidney_dose=20.0,\n",
    "    egfr=35,\n",
    "    predicted_lu_dose=29.4,\n",
    "    kidney_history=\"Stage 3b CKD\"\n",
    ")\n",
    "\n",
    "print(recommendation)"
   ]
  },
  {
   "cell_type": "markdown",
   "id": "72fe3161-3c7e-445e-ac47-873edda8105c",
   "metadata": {},
   "source": [
    "---\n",
    "\n",
    "## Summary & Clinical Impact üéØ\n",
    "\n",
    "**What This Demo Shows:**\n",
    "\n",
    "‚úÖ **AI interprets dosimetry in clinical context**\n",
    "   - Not just numbers, but actionable recommendations\n",
    "   - EANM guideline integration\n",
    "   - Risk stratification (clear/borderline/high-risk)\n",
    "\n",
    "‚úÖ **Nuanced clinical judgment**\n",
    "   - Case 1: Standard protocol appropriate\n",
    "   - Case 2: Eligible WITH dose modifications (5.5 GBq, extended cycles)\n",
    "   - Case 3: High risk, requires major dose reduction or alternatives\n",
    "\n",
    "‚úÖ **Structured output clinicians can use**\n",
    "   - Eligibility decision\n",
    "   - Key considerations\n",
    "   - Dose recommendations\n",
    "   - Monitoring protocols\n",
    "\n",
    "---\n",
    "\n",
    "## Technical Architecture\n",
    "\n",
    "**Dosimetry Pipeline (Pseudocode Provided):**\n",
    "- Z-Rad: Vendor-neutral SUV extraction\n",
    "- TotalSegmentator: AI organ segmentation  \n",
    "- MIRD formalism: Absorbed dose calculation\n",
    "\n",
    "**AI Clinical Layer (Demonstrated Here):**\n",
    "- Gemini 2.5-flash (HAI-DEF)\n",
    "- Evidence-based guideline interpretation\n",
    "- Structured clinical decision support\n",
    "\n",
    "---\n",
    "\n",
    "## Impact for Resource-Limited Settings üåç\n",
    "\n",
    "**This system enables:**\n",
    "- Safer Lu-177 therapy implementation\n",
    "- Evidence-based patient selection\n",
    "- Prevention of inappropriate exclusions\n",
    "- Identification of high-risk patients\n",
    "\n",
    "**Without requiring:**\n",
    "- Expensive proprietary software ($10,000-50,000)\n",
    "- Manual guideline review for every patient\n",
    "- Deep dosimetry expertise at every site\n",
    "\n",
    "---\n",
    "\n",
    "## Next Steps üöÄ\n",
    "\n",
    "**Short-term:** Process real DICOM data, validate against OLINDA/EXM\n",
    "\n",
    "**Medium-term:** Multi-center deployment across East Africa\n",
    "\n",
    "**Long-term:** Extend to other theranostic pairs (DOTATATE, FAP inhibitors)\n",
    "\n",
    "---\n",
    "\n",
    "**Contact:** Amy Siele | University of Nairobi | RFH Healthcare Kenya"
   ]
  },
  {
   "cell_type": "code",
   "execution_count": null,
   "id": "0ffee2e8-a531-46ad-aad2-0793d2b08d67",
   "metadata": {},
   "outputs": [],
   "source": []
  }
 ],
 "metadata": {
  "kernelspec": {
   "display_name": "Python 3 (ipykernel)",
   "language": "python",
   "name": "python3"
  },
  "language_info": {
   "codemirror_mode": {
    "name": "ipython",
    "version": 3
   },
   "file_extension": ".py",
   "mimetype": "text/x-python",
   "name": "python",
   "nbconvert_exporter": "python",
   "pygments_lexer": "ipython3",
   "version": "3.11.14"
  }
 },
 "nbformat": 4,
 "nbformat_minor": 5
}
